CXCL8 and renal cell carcinoma: Similar data were reported in individual studies by Yuen et al.29and Schalper et al.,31 showing a significant detrimental effect of high IL-8 circulating levels only in cohorts of RCC patients receiving single-agent atezolizumab, nivolumab, or everolimus, but not a combination of atezolizumab and bevacizumab or sunitinib alone.